0 11 Stimulation stimulation NN 12 14 of of IN 15 16 a a DT 17 22 human human JJ 23 29 T-cell t-cell NN 30 35 clone clone NN 36 40 with with IN 41 49 anti-CD3 anti-cd3 NN 50 52 or or CC 53 58 tumor tumor NN 59 67 necrosis necrosis NN 68 74 factor factor NN 75 82 induces induce VBZ 83 91 NF-kappa NF-kappa NNP 92 93 B B NNP 94 107 translocation translocation NN 108 111 but but CC 112 115 not not RB 116 121 human human JJ 122 138 immunodeficiency immunodeficiency NN 139 144 virus virus NN 145 146 1 1 CD 147 165 enhancer-dependent enhancer-dependent JJ 166 179 transcription transcription NN 179 180 . . . 182 185 The the DT 186 196 expression expression NN 197 199 of of IN 200 211 transiently transiently RB 212 223 transfected transfecte VBN 224 234 expression expression NN 235 242 vectors vector NNS 243 248 under under IN 249 252 the the DT 253 260 control control NN 261 263 of of IN 264 267 the the DT 268 272 long long JJ 273 281 terminal terminal JJ 282 288 repeat repeat NN 289 290 ( ( ( 290 293 LTR LTR NNP 293 294 ) ) ) 295 297 of of IN 298 301 the the DT 302 307 human human JJ 308 324 immunodeficiency immunodeficiency NN 325 330 virus virus NN 331 332 ( ( ( 332 335 HIV HIV NNP 335 336 ) ) ) 337 339 or or CC 340 343 its its PRP$ 344 352 enhancer enhancer NN 353 361 sequence sequence NN 362 365 and and CC 366 369 the the DT 370 383 translocation translocation NN 384 386 of of IN 387 390 the the DT 391 394 HIV HIV NNP 395 411 enhancer-binding enhancer-binding JJ 412 419 protein protein NN 420 428 NF-kappa NF-kappa NNP 429 430 B B NNP 431 435 were be VBD 436 444 analyzed analyze VBN 445 447 in in IN 448 451 two two CD 452 457 human human JJ 458 464 T-cell t-cell NN 465 471 clones clone NNS 472 482 stimulated stimulate VBN 483 490 through through IN 491 496 their their PRP$ 497 503 T-cell t-cell NN 504 512 receptor receptor NN 513 520 complex complex NN 521 523 or or CC 524 526 by by IN 527 532 tumor tumor NN 533 541 necrosis necrosis NN 542 548 factor factor NN 549 551 or or CC 552 559 phorbol phorbol NN 560 572 12-myristate 12-myristate NN 573 583 13-acetate 13-acetate NN 583 584 . . . 585 587 We we PRP 588 593 found find VBD 594 595 a a DT 596 608 dissociation dissociation NN 609 611 of of IN 612 620 NF-kappa NF-kappa NNP 621 622 B B NNP 623 636 translocation translocation NN 637 641 from from IN 642 657 transactivation transactivation NN 658 660 of of IN 661 667 either either CC 668 671 the the DT 672 675 HIV HIV NNP 676 679 LTR LTR NNP 680 682 or or CC 683 686 the the DT 687 690 HIV HIV NNP 691 699 enhancer enhancer NN 699 700 . . . 701 712 Interleukin Interleukin NNP 713 714 2 2 CD 715 722 induced induce VBD 723 736 proliferation proliferation NN 737 740 but but CC 741 744 not not RB 745 753 NF-kappa NF-kappa NNP 754 755 B B NNP 756 769 translocation translocation NN 770 772 or or CC 773 776 LTR ltr NN 777 792 transactivation transactivation NN 792 793 . . . 794 801 Phorbol Phorbol NNP 802 807 ester ester NN 808 810 or or CC 811 819 specific specific JJ 820 827 antigen antigen NN 828 839 recognition recognition NN 840 847 induced induce VBD 848 851 HIV HIV NNP 852 855 LTR LTR NNP 856 871 transactivation transactivation NN 871 872 , , , 873 880 whereas whereas IN 881 892 stimulation stimulation NN 893 897 with with IN 898 903 tumor tumor NN 904 912 necrosis necrosis NN 913 919 factor factor NN 920 922 or or CC 923 931 antibody antibody NN 932 934 to to TO 935 938 CD3 CD3 NNP 939 942 did do VBD 943 946 not not RB 946 947 . . . 948 951 The the DT 952 955 two two CD 956 962 latter latter JJ 963 970 signals signal NNS 971 975 were be VBD 976 988 nevertheless nevertheless RB 989 993 able able JJ 994 996 to to TO 997 1003 induce induce VB 1004 1012 NF-kappa NF-kappa NNP 1013 1014 B B NNP 1015 1028 translocation translocation NN 1029 1033 with with IN 1034 1035 a a DT 1036 1043 pattern pattern NN 1044 1046 in in IN 1047 1050 the the DT 1051 1061 band-shift band-shift NN 1062 1067 assay assay NN 1068 1085 indistinguishable indistinguishable JJ 1086 1090 from from IN 1091 1095 that that DT 1096 1104 observed observe VBN 1105 1110 using use VBG 1111 1118 phorbol phorbol NN 1119 1124 ester ester NN 1124 1125 . . . 1126 1129 Our our PRP$ 1130 1137 finding finding NN 1138 1142 that that IN 1143 1152 induction induction NN 1153 1155 of of IN 1156 1164 NF-kappa NF-kappa NNP 1165 1166 B B NNP 1167 1169 by by IN 1170 1175 tumor tumor NN 1176 1184 necrosis necrosis NN 1185 1191 factor factor NN 1192 1194 or or CC 1195 1203 antibody antibody NN 1204 1206 to to TO 1207 1210 CD3 CD3 NNP 1211 1213 is be VBZ 1214 1217 not not RB 1218 1228 sufficient sufficient JJ 1229 1231 to to TO 1232 1238 induce induce VB 1239 1242 HIV HIV NNP 1243 1261 enhancer-dependent enhancer-dependent JJ 1262 1275 transcription transcription NN 1276 1278 in in IN 1279 1285 cloned clone VBN 1286 1287 T t NN 1288 1293 cells cell NNS 1294 1303 contrasts contrast VBZ 1304 1308 with with IN 1309 1316 results result NNS 1317 1325 obtained obtain VBN 1326 1328 in in IN 1329 1333 most most JJS 1334 1348 lymphoblastoid lymphoblastoid JJ 1349 1355 T-cell t-cell NN 1356 1361 lines line NNS 1362 1365 and and CC 1366 1375 indicates indicate VBZ 1376 1380 that that IN 1381 1387 normal normal JJ 1388 1389 T t NN 1390 1401 lymphocytes lymphocyte NNS 1402 1408 differ differ VBP 1409 1413 from from IN 1414 1421 tumoral tumoral JJ 1422 1423 T t NN 1424 1429 cells cell NNS 1430 1432 in in IN 1433 1438 terms term NNS 1439 1441 of of IN 1442 1454 requirements requirement NNS 1455 1458 for for IN 1459 1462 HIV HIV NNP 1463 1466 LTR LTR NNP 1467 1477 activation activation NN 1477 1478 . . . 1479 1490 Furthermore furthermore RB 1490 1491 , , , 1492 1495 our our PRP$ 1496 1503 results result NNS 1504 1511 suggest suggest VBP 1512 1516 that that IN 1517 1523 events event NNS 1524 1530 linked link VBN 1531 1533 to to TO 1534 1540 T-cell t-cell NN 1541 1551 activation activation NN 1551 1552 , , , 1553 1555 in in IN 1556 1564 addition addition NN 1565 1567 to to TO 1568 1576 NF-kappa NF-kappa NNP 1577 1578 B B NNP 1579 1592 translocation translocation NN 1593 1596 per per FW 1597 1599 se se FW 1599 1600 , , , 1601 1607 induce induce VBP 1608 1618 functional functional JJ 1619 1631 interactions interaction NNS 1632 1634 of of IN 1635 1638 the the DT 1639 1647 NF-kappa NF-kappa NNP 1648 1649 B B NNP 1650 1657 complex complex NN 1658 1662 with with IN 1663 1666 the the DT 1667 1670 HIV HIV NNP 1671 1679 enhancer enhancer NN 1679 1680 . . .